The prostaglandin pathway has been targeted for colon cancer chemoprevention by steroids that inhibit arachidonic acid release, and by nonsteroidal anti-inflammatory agents (NSAIDs) that block COX-1 and COX-2 [54]. Here, PTGS2 is linked to colonic neoplasm.